The hypothesis is that renal function will improve following tricuspid valve intervention. A reduction in renal biomarkers is also expected. Furthermore, based on previous assessments, it is anticipated that there will be an improvement in volume status (reduced edema), symptom burden, and physical capacity in patients. Additionally, the study will assess the impact of the intervention on functional parameters such as motor capacity, physical activity, performance of activities of daily living, and ultimately, participation and quality of life.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Change in estimated glomerular filtration rate (eGFR) slope
Timeframe: Baseline, 6 months, 12 months, and 24 months
Incidence of acute kidney injury (AKI)
Timeframe: Baseline, 6 months, 12 months, and 24 months
Physical activity assessed using the activPAL4 micro activity monitor
Timeframe: Baseline, 6 months, 12 months, and 24 months
Change in functional exercise capacity assessed with the 6-minute walk test (6MWT)
Timeframe: Baseline, 6 months, 12 months, and 24 months